Literature DB >> 24315367

Does reduced creatine synthesis protect against statin myopathy?

Kevin D Ballard1, Paul D Thompson.   

Abstract

Statins, widely used to lower cholesterol levels, cause myopathy in some patients. Mangravite et al. (2013) show that a single nucleotide polymorphism decreasing expression of glycine amidinotransferase (GATM), the enzyme regulating creatine biosynthesis, is associated with reduced statin myopathy. Whether reduced creatine production protects against statin myopathy remains to be determined.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24315367      PMCID： PMC3899594          DOI： 10.1016/j.cmet.2013.11.012

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  10 in total

1.  Creatine supplementation prevents statin-induced muscle toxicity.

Authors:  David A Shewmon; John M Craig
Journal:  Ann Intern Med       Date:  2010-11-16       Impact factor: 25.391

2.  l-arginine:glycine amidinotransferase (AGAT) deficiency: clinical presentation and response to treatment in two patients with a novel mutation.

Authors:  Simon Edvardson; Stanley H Korman; Amir Livne; Avraham Shaag; Ann Saada; Ruppen Nalbandian; Hyla Allouche-Arnon; J Moshe Gomori; Rachel Katz-Brull
Journal:  Mol Genet Metab       Date:  2010-07-07       Impact factor: 4.797

3.  Mechanisms of statin-induced myalgia assessed by physiogenomic associations.

Authors:  Gualberto Ruaño; Andreas Windemuth; Alan H B Wu; John P Kane; Mary J Malloy; Clive R Pullinger; Mohan Kocherla; Kali Bogaard; Bruce R Gordon; Theodore R Holford; Ankur Gupta; Richard L Seip; Paul D Thompson
Journal:  Atherosclerosis       Date:  2011-07-20       Impact factor: 5.162

4.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

Authors:  Deepak Voora; Svati H Shah; Ivan Spasojevic; Shazia Ali; Carol R Reed; Benjamin A Salisbury; Geoffrey S Ginsburg
Journal:  J Am Coll Cardiol       Date:  2009-10-20       Impact factor: 24.094

5.  Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity.

Authors:  Ravi K Mareedu; Falgun M Modhia; Elenita I Kanin; James G Linneman; Terrie Kitchner; Catherine A McCarty; Ronald M Krauss; Russell A Wilke
Journal:  Prev Cardiol       Date:  2009

Review 6.  The genetics of statin-induced myopathy.

Authors:  Abhijit Ghatak; Osman Faheem; Paul D Thompson
Journal:  Atherosclerosis       Date:  2009-11-27       Impact factor: 5.162

7.  SLCO1B1 variants and statin-induced myopathy--a genomewide study.

Authors:  E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins
Journal:  N Engl J Med       Date:  2008-07-23       Impact factor: 91.245

Review 8.  Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies.

Authors:  Payam Mohassel; Andrew L Mammen
Journal:  Muscle Nerve       Date:  2013-08-30       Impact factor: 3.217

9.  Effect of statins on skeletal muscle function.

Authors:  Beth A Parker; Jeffrey A Capizzi; Adam S Grimaldi; Priscilla M Clarkson; Stephanie M Cole; Justin Keadle; Stuart Chipkin; Linda S Pescatello; Kathleen Simpson; C Michael White; Paul D Thompson
Journal:  Circulation       Date:  2012-11-26       Impact factor: 29.690

10.  A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.

Authors:  Lara M Mangravite; Barbara E Engelhardt; Marisa W Medina; Joshua D Smith; Christopher D Brown; Daniel I Chasman; Brigham H Mecham; Bryan Howie; Heejung Shim; Devesh Naidoo; QiPing Feng; Mark J Rieder; Yii-Der I Chen; Jerome I Rotter; Paul M Ridker; Jemma C Hopewell; Sarah Parish; Jane Armitage; Rory Collins; Russell A Wilke; Deborah A Nickerson; Matthew Stephens; Ronald M Krauss
Journal:  Nature       Date:  2013-08-28       Impact factor: 49.962
  10 in total
  6 in total

Review 1.  Mechanisms and assessment of statin-related muscular adverse effects.

Authors:  Dirk Moßhammer; Elke Schaeffeler; Matthias Schwab; Klaus Mörike
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

2.  GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals.

Authors:  Jasmine A Luzum; Joseph P Kitzmiller; Paul J Isackson; Changxing Ma; Marisa W Medina; Anees M Dauki; Eduard B Mikulik; Heather M Ochs-Balcom; Georgirene D Vladutiu
Journal:  Cell Metab       Date:  2015-04-07       Impact factor: 27.287

Review 3.  Combining genetic and nongenetic biomarkers to realize the promise of pharmacogenomics for inflammatory diseases.

Authors:  Joseph C Maranville; Anna Di Rienzo
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

4.  The adjuvant value of Herba Cistanches when used in combination with statin in murine models.

Authors:  Elaine Wat; Chun Fai Ng; Chi Man Koon; Cheng Zhang; Si Gao; Brian Tomlinson; Clara Bik San Lau
Journal:  Sci Rep       Date:  2017-08-24       Impact factor: 4.379

Review 5.  Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.

Authors:  William J Canestaro; Melissa A Austin; Kenneth E Thummel
Journal:  Genet Med       Date:  2014-05-08       Impact factor: 8.822

6.  The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis.

Authors:  Mengyuan Liu; Fangfang Fan; Yan Zhang; Jianping Li
Journal:  Eur J Clin Pharmacol       Date:  2020-10-13       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.